Indaptus Therapeutics, Inc. (INDP) Key Metrics
INDP valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $350.4M
- Enterprise value
- $496.5M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 44.2
- EV / EBITDA
- 1.0
- Dividend yield
- —
- Beta
- 0.97
INDP key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsINDP returns How much profit the business earns on the capital it uses.
INDP financial health Debt, liquidity and how easily interest is covered.
INDP returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
INDP debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
INDP key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Share price at fiscal year-end | $2.91 | $23.58 | $49.28 | $40.60 | $159.60 | $386.40 | $1,120.00 | $16,889.60 | $11,536.00 | $12,768.00 |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −587.6% | −187.5% | −84.0% | −47.3% | −43.2% | — | −146.3% | −77.5% | −70.9% | −45.8% |
| Return on invested capital (ROIC) | — | — | — | — | — | — | −349.9% | −413.6% | −581.6% | −237.2% |
| Return on assets (ROA) | −250.5% | −135.0% | −71.8% | −41.7% | −36.4% | −31.1% | −115.0% | −69.1% | −64.8% | −43.1% |
| Return on tangible assets | −223.9% | −204.7% | −103.3% | −51.0% | −19.0% | −201.6% | −223.7% | −70.8% | −44.8% | −54.1% |
| Financial health | ||||||||||
| Total debt | — | $84,164 | $175,053 | $80,494 | $169,327 | $169,327 | $1.3M | — | — | — |
| Cash & short-term investments | $8.5M | $5.8M | $13.4M | $26.4M | $39.1M | $1.6M | $10.1M | $40.6M | $55.2M | $18.3M |
| Net debt | −$8.5M | −$5.7M | −$13.2M | −$26.4M | −$39.0M | −$1.5M | −$8.7M | −$40.6M | −$55.2M | −$18.3M |
| Debt / equity | — | 0.02 | 0.01 | 0.00 | 0.00 | — | 0.12 | — | — | — |
| Debt / assets | — | 0.01 | 0.01 | 0.00 | 0.00 | 0.10 | 0.06 | — | — | — |
| Current ratio | 1.51 | 1.95 | 5.05 | 7.94 | 8.77 | 0.86 | 1.65 | 5.69 | 9.80 | 10.77 |
| Quick ratio | 1.51 | 1.95 | 5.05 | 7.94 | 8.77 | 0.86 | 1.65 | 5.69 | 9.80 | 10.77 |
| Interest coverage | — | — | — | -25.4 | -436.1 | -238.1 | — | — | — | -865.4 |
| Working capital | $3.2M | $3.2M | $11.2M | $23.8M | $35.8M | −$283,495 | $5.4M | $35.9M | $50.6M | $18.8M |
| Invested capital | −$5.4M | −$1.8M | −$1.1M | −$1.7M | −$3.1M | −$1.7M | $2.8M | $13.0M | $3.6M | $4.4M |
| Tangible asset value | $3.2M | $3.9M | $12.1M | $24.6M | $35.9M | −$237,701 | $11.5M | $53.5M | $58.8M | $22.7M |
| Net current asset value | $3.2M | $3.2M | $11.1M | $23.8M | $35.7M | −$283,495 | $4.0M | $35.6M | $50.6M | $18.7M |
| Capital allocation | ||||||||||
| Capex / depreciation | — | 0.00 | 0.00 | 96.89 | 2.75 | 9,634.24 | 1.08 | 11.17 | 6.03 | 0.69 |
| Efficiency | ||||||||||
| Days payables outstanding | — | 416,207.5 | 310,466.0 | 411,534.1 | 363,408.2 | 784,612.3 | 1,358.3 | 999.2 | 661.8 | 460.1 |
| Receivables turnover | — | — | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.27 | 0.37 | 0.55 | 0.79 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | — | — | — | $21,056 | — | $2.8M | $1.3M | $599,500 | $751,654 |
| Average payables | $707,143 | $838,116 | $1.1M | $2.0M | $1.4M | $1.8M | $3.2M | $2.4M | $1.5M | $883,629 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from INDP's annual financial statements (latest annual report filed March 17, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
INDP valuation and financial ratios
Indaptus Therapeutics earned a return on equity of −587.6% in fiscal 2025.
See the INDP income statement, the INDP chart for price history, or the INDP stock overview for the latest quote and news.
INDP key metrics FAQ
What is Indaptus Therapeutics's return on equity?
Indaptus Therapeutics's return on equity (ROE) was −587.6% in fiscal 2025: net income of -$20.8 million on average shareholders' equity of $3.5 million.
What is Indaptus Therapeutics's current ratio?
Indaptus Therapeutics's current ratio was 1.51 at the end of fiscal 2025: current assets were 1.51 times current liabilities.